SCHEMBL2924716

SCHEMBL2924716

CCC=C(C(=O)OCC)C(=O)c1cc(F)c(F)c(Br)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
NPSR1 Q6W5P4 5/20 0.40
LMNA P02545 4/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
MAPK1 P28482 2/20 0.40
CYP2C9 P11712 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
GLO1 Q04760 1/20 0.34
DHODH Q02127 3/20 0.33
GPR35 Q9HC97 1/20 0.33
GAA P10253 2/20 0.32
PTP4A1 Q93096 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
PLIN1 O60240 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10774566 0.89 GPR35 (0.39) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL7054038 0.88 MEN1 (0.42) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL7010290 0.86 MAPT (0.41) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL2924710 0.86 MAPT (0.39) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL2924713 0.86 MAPT (0.39) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL9096775 0.86 MAPT (0.39) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL5525147 0.84 NPSR1 (0.40) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL10692113 0.84 MAPT (0.41) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL9183132 0.84 CYP2D6 (0.40) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL8802596 0.84 CYP2D6 (0.40) MAPTMEN1KMT2ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813610-B1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF WAKUNAGA PHARMA CO LTD (JP) 2010-09-08 EP disclosed
US-7713997-B2 Pyridonecarboxylic acid derivatives or salts thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2010-05-11 US disclosed
US-20090149440-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD (JP) 2009-06-11 US disclosed
EP-1813610-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed
US-6858625-B1 Quinolinecarboxylic acid derivative or salts thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2005-02-22 US disclosed
EP-0952151-B1 Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts WAKUNAGA PHARMA CO LTD (JP) 2003-05-28 EP disclosed
EP-0992501-B1 Pyridonecarboxylic acid derivatives as antibacterial agents WAKUNAGA PHARMA CO LTD (JP) 2002-08-28 EP disclosed
EP-1193266-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2002-04-03 EP disclosed
EP-0911327-B1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT WAKUNAGA PHARMA CO LTD (JP) 2001-12-05 EP disclosed
US-6156903-A Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2000-12-05 US disclosed
US-5998436-A Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) 1999-12-07 US disclosed
EP-0952151-A2 Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 1999-10-27 EP disclosed
EP-0911327-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 1999-04-28 EP disclosed
EP-0184035-B1 QUINOLONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION KYORIN PHARMACEUTICAL CO., LTD. (JP) 1990-07-25 EP disclosed
EP-0216245-B1 QUINOLONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION KYORIN PHARMACEUTICAL CO., LTD. (JP) 1990-07-25 EP disclosed
EP-0183129-B1 QUINOLONECARBOXYLIC ACID DERIVATIVES KYORIN PHARMACEUTICAL CO., LTD. (JP) 1989-08-09 EP disclosed
US-4826982-A BACTERICIDES KYORIN PHARMACEUTICAL CO., LTD. (JP) 1989-05-02 US disclosed
EP-0216245-A1 Quinolonecarboxylic acid derivatives and process for their preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 1987-04-01 EP disclosed
EP-0184035-A1 Quinolonecarboxylic acid derivatives and process for their preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 1986-06-11 EP disclosed
EP-0183129-A1 Quinolonecarboxylic acid derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 1986-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149440-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF SLC7A1, PLPBP, PYCR1 MAPT 4419/4885MEN1 4165/4885KMT2A 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.